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Lastly, it is important to note that
a sizable fraction of the general population
(2.5%) harbors single-nucleotide polymor-
phisms that inactivate the tumor sup-
pressoractivityofPTPN12,but themajority
of these individuals do not develop cancer.
Therefore, loss of PTPN12 alone is not
sufficient to drive tumor formation. Inter-
estingly, the effect of PTPN12 appears
confined to theERK/RSKpathway,without
affecting the important PI3K/Akt pathway.
This observation suggests that PTPN12
loss cooperates with mutations in other
pathways, including thePI3K/Aktpathway,
which is hyperactivated in nearly 50% of640 Cell 144, March 4, 2011 ª2011 Elsevier Ibreast cancers. These considerations
together lead us to conclude that, although
PTPN12 may be an important piece of the
triple-negative breast cancer puzzle, it is
still a member of an even larger constella-
tion of alterations that together drive this
recalcitrant malignancy.REFERENCES
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The target of rapamycin complex 2 (TORC2) is a key regulator of cell growth. Zinzalla et al. (2011)
now provide evidence that TORC2 is activated by direct association with the ribosome, which
may ensure that TORC2 activity is calibrated to match the cell’s intrinsic growth capacity.TOR is an atypical serine/threonine
protein kinase conserved from yeast to
mammals that forms two distinct physical
and functional complexes termed TORC1
and TORC2 (Figure 1) (Wullschleger et al.,
2006). TORC1, a rapamycin-sensitive
complex, regulates translation, autoph-
agy, cell growth, and cell size. In contrast,
TORC2 is not directly inhibited by rapa-
mycin and controls cell survival and
morphology. The frequent dysregulation
of mammalian TOR (mTOR) signaling
observed in human cancer is thought to
contribute to tumorigenesis (Zoncu
et al., 2011). Extensive studies have re-
vealed the molecular mechanisms of
mTORC1 regulation in response to
signals, such as growth factors, cellular
energy status, nutrient availability, and
stress. Although compelling evidencehas placed TORC2 downstream of phos-
phatidylinositol 3-kinase (PI3K) and
upstream of the serine/threonine kinase
AKT, it has been unknown how TORC2
is regulated (Wullschleger et al., 2006).
Using a combination of elegant genetic
screening and sophisticated biochemical
studies, Zinzalla et al. (2011) significantly
advance our understanding of TOR
biology by identifying the ribosome as
a missing link between PI3K and
mTORC2 (Figure 1).
In yeast, TORC2 phosphorylates and
activates YPK2, the ortholog of mamma-
lian kinase SGK1, a known substrate of
mammalian TORC2. Loss of TORC2 func-
tion is lethal in yeast; however, overex-
pression of a constitutively active YPK2
suppresses the lethality caused by
a loss-of-function TORC2 mutation(Kamada et al., 2005). Zinzalla et al. de-
signed a clever reverse suppressor
screen in search of yeast mutants that
require the expression of constitutively
active YPK2 for survival. This strategy
was aimed at uncovering mutations in
TORC2 upstream activators. Perhaps
not surprisingly, many mutations isolated
were found in genes encoding compo-
nents of TORC2. Interestingly, the only
non-TORC2 component isolated was
NIP7, which encodes a protein involved
in the maturation of rRNA and ribosome
biogenesis. Survival of NIP7 mutant yeast
requires overexpression of the constitu-
tively active YPK2. Many scientists would
abstain from studying ribosomal proteins
because their inactivation may disrupt
protein translation and lead to pleiotropic
effects. Undeterred, Hall and colleagues
Figure 1. Regulation of TORC2 by PI3K and Ribosome Association
In response to upstream stimulation, increased phosphatidylinositol 3-kinase
(PI3K) signaling activates mTORC2 (consisting of mTOR, Rictor, Sin1, and
mLST8) by promoting its association with ribosomes. mTORC2 phosphory-
lates the C-terminal turn motif (T450) and hydrophobic motif (S473) in AKT.
AKT activation also requires phosphorylation of the activation loop (T308) by
PDK1. Notably, phosphorylation of the turn motif of AKT is constitutive and
cotranslational, whereas phosphorylation of the hydrophobic motif is highly
dependent on PI3K signaling and posttranslational. TORC2 similarly phos-
phorylates the turn motif and hydrophobic motif in SGK and conventional
protein kinase C (Garcı´a-Martı´nez and Alessi, 2008; Jacinto et al., 2004; Sar-
bassov et al., 2005).investigated further, eventu-
ally discovering an exciting
biochemical mechanism link-
ing the ribosome to TORC2
activation.
The genetic studies not
only confirm a role for NIP7
in TORC2 activation, but also
show that ribosomal proteins
are important for TORC2
function in yeast. Mutation of
NIP7 mimics the TORC2
loss-of-function phenotypes,
indicating a strong functional
relationship between these
two genes. The authors
further extended their study
to mammalian cells and
show that mammalian NIP7
(mNIP7) and ribosome
assembly are important for
mTORC2 activation. Knock-
down of mNIP7 reduces
mTORC2 activity, as indi-
cated by a decrease in the
phosphorylation of mTORC2
substrates. Moreover, knock-
down of either Rpl7 (a subunit
of the 60S ribosome) or
Rps16 (a subunit of the
40S ribosome) inactivatesmTORC2, demonstrating the importance
of ribosome in mTORC2 activation. Inhibi-
tion of protein translation had no effect on
mTORC2 activation, supporting the
notion that mTORC2 is activated by the
ribosome, but not translation. Addition-
ally, extensive biochemical studies
demonstrate that mTORC2 can associate
with the ribosome, and the ribosomal-
associated mTORC2 displays kinase
activity toward AKT in vitro. It appears
that the mTORC2 components, rictor
and/or sin1, which are not found in
TORC1, interact with the 60S subunit of
ribosome.
Importantly, the authors link this associ-
ation with known upstream regulators of
TORC2, demonstrating that the interaction
between ribosome and TORC2 is strongly
enhanced by insulin stimulation. Inhibition
of PI3K activity blocks the interaction
between the ribosome and mTORC2, as
well as inhibits mTORC2 activation in
response to insulin. Complementary acti-
vation of PI3K by knockdown of PTEN—
a tumor suppressor lipid phosphatase
that counters PI3K signaling—increasesthe interaction between mTORC2 and
ribosome, demonstrating the necessary
and sufficient role of PI3K in regulating
the mTORC2-ribosomal association and
thus mTORC2 activation. The role of PI3K
in promoting the interaction of mTORC2
and ribosome was further validated in
multiple cancer cell lines with high PI3K
signaling. Collectively, the study by Zin-
zalla et al. has convincingly demonstrated
that the PI3K-dependent mTORC2-
ribosome interaction plays a major role in
TORC2 activation. Interestingly, Oh et al.
(2010) have also recently reported the
association of mTORC2with the ribosome
and propose that the ribosomal associa-
tion is important for the cotranslational
phosphorylation of the AKT turn motif.
The findings of Zinzalla et al. raise many
interesting questions. How is the interac-
tion between mTORC2 and the ribosome
regulated? There may be intermediate
players between PI3K and the TORC2-
ribosome interaction. For example, phos-
phorylation of rictor may play a role
(Dibble et al., 2009; Treins et al., 2010).
Is the interaction between TORC2 andCell 144, March 4the ribosome regulated in
yeast? And if so, by what
signals? The TORC2-ribo-
some interaction is conserved
from yeast to mammals;
however, there is no evidence
that yeast TORC2 is activated
in a PI3K-dependent manner
as in mammalian cells.
How could mTORC2 be
responsible for phosphory-
lating two different sites on
the same protein with drasti-
cally different manners of
regulation? mTORC2 phos-
phorylates both the hydro-
phobic motif and the turn
motif of AKT. Notably, phos-
phorylation of the hydro-
phobic motif is posttransla-
tional and induced in a
PI3K-dependent manner,
whereas phosphorylation of
the turn motif is cotransla-
tional and constitutive (Oh
et al., 2010). Ribosomal
association may explain the
constitutive and cotransla-
tional phosphorylation of the
turn motif in AKT (Figure 1).
Membrane association hasbeen suggested to be important for
AKT hydrophobic motif phosphorylation.
Does this imply that there are two
different pools of mTORC2?
What is the exact role of the ribosome in
mTORC2 activation? Does ribosome
binding regulate mTORC2 function by
affecting localization, contributing to acti-
vation, or maintaining an active mTORC2
kinase?
Lastly, why the ribosome? As pointed
out by Zinzalla et al., ribosome content
reflects the cell’s potential for growth.
Therefore, a mechanism that involves
the ribosome may ensure that TORC2
activation is tightly linked with the cell’s
ability to respond to growth signals. In
addition, given that TORC1 regulates
ribosome biogenesis, this study suggests
a possible interplay between the two
TORC complexes, in which TORC2
modulates TORC1 by activating AKT
and TORC1 affects TORC2 by increasing
ribosomal biogenesis and S6K-mediated
feedback inhibition. Future studies are
needed to address these important ques-
tions and possible new roles of the, 2011 ª2011 Elsevier Inc. 641
ribosome in cellular signaling, especially
in the regulation of cell growth.REFERENCES
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Sex steroids, including testosterone, regulate the development and function of the male skeleton.
Oury et al. (2011) identify a surprising new connection between the skeleton and the testis, which
has implications for male fertility. They show that testosterone production in the testis is directly
influenced by the bone-derived hormone osteocalcin.The sex steroids testosterone and
estrogenare essential regulators of fertility.
Acting through nuclear hormone receptors
expressed in somatic cells, testosterone
regulates the development and mainte-
nance of the male reproductive system
and, by modulating the activity of support
cells, promotes germ cell survival. Testos-
terone synthesis occurs within Leydig cells
in the testes and is regulated by luteinizing
hormone (LH) produced by the pituitary
gland. In addition to LH and follicle-stimu-
lating hormone (which is also secreted
from the pituitary), there is emerging
evidence that metabolic hormones such
as leptin (Tena-Sempere and Barreiro,
2002) and insulin (Ma and Wittert, 2010)
have impacts on testis function.
Now, Oury et al. (2011) demonstrate
that the skeleton may play a previously
unforeseen role in control of male fertility,
showing that osteocalcin (Ocn), a peptide
hormone that is secreted by bone-form-ing osteoblast cells, directly controls
testosterone production by Leydig cells
in the testis (Figure 1). Using ex vivo cell
assays, the authors demonstrate that
a factor that is secreted by osteoblasts,
but not other skeletal cell-types, markedly
increases testosterone production both
by testis explants and by isolated Leydig
cells. Speculating that this effect is likely
tobemediatedbyosteocalcin, theauthors
show that this response is lost when Ocn-
deficient osteoblasts are used but is
rescued in a dose-dependent manner by
introduction of exogenous osteocalcin.
Injection of osteocalcin also increases
serum testosterone in mice. Together,
these data strongly suggest that osteocal-
cin is indeedoneof theosteoblast-secreted
factors that are responsible for enhanced
testosterone production.
To support their in vitro data, the authors
exploit two mouse models in which osteo-
calcin function is either ablated (Ocnknockout mice) or enhanced (Esp
knockout mice, which lack an osteotestic-
ular phosphatase that negatively
regulates osteocalcin maturation).
Compared to controls, testis weight,
sperm counts, and levels of circulating
testosterone are all significantly reduced
in Ocn knockout mice and conversely
increased in Esp knockout males. Consis-
tent with these physiological changes,
Ocn-deficient males sire fewer offspring
than controls, although no significant
increase is observed using Esp-deficient
males, possibly because the availability of
oocytes acts as a limiting factor. Tissue-
specific ablation of these genes in bone
or testis confirms that osteocalcin derived
from the skeleton acts as an endocrine
factor to regulate male fertility.
How does osteocalcin influence testo-
sterone synthesis? To identify the receptor
through which osteocalcin signals, the
authors postulate that, because the
